APPLICATION
NDA213400
TYPE
NDA
ORIGINAL APPROVAL
2020-06-18
LATEST ACTION
2020-06-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
TAZVERIKPrescription
TAZEMETOSTAT HYDROBROMIDE 200MG · TABLET · ORAL
Approval history
2020-06-18Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · Original · priority — Label ↗AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.